#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Greg Moeck Email
VP, Microbiology . VenatoRx Pharmaceuticals
How to contact Greg Moeck
Join and see Greg's contact info for free!Phone
Current Roles
Employees:
77Revenue:
$15.5MAbout
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.VenatoRx Pharmaceuticals Address
74 E. Swedesford RoadMalvern, PA
United States